We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+30.48%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$621M
AUM Growth
+$72.3M
Cap. Flow
-$24.9M
Cap. Flow %
-4%
Top 10 Hldgs %
33.04%
Holding
112
New
30
Increased
19
Reduced
32
Closed
13

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.5M
2
NVMI
Nova
NVMI
+$15.3M
3
GLBE icon
Global E Online
GLBE
+$9.72M
4
TBLA icon
Taboola.com
TBLA
+$6.52M
5
META icon
Meta Platforms (Facebook)
META
+$6.21M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$6.82M
2
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$6.35M
3
AMZN icon
Amazon
AMZN
+$5.55M
4
IRON icon
Disc Medicine
IRON
+$5.23M
5
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$4.67M

Sector Composition

Rank Sector Weight
1 Healthcare 63.14%
2 Technology 15.8%
3 Communication Services 3.76%
4 Consumer Discretionary 3.08%
5 Utilities 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
26
Eli Lilly
LLY
$1.02T
$8.27M 1.33%
14,190
– –
DAWN
27
DELISTED
Day One Biopharmaceuticals
DAWN
$7.49M 1.21%
513,000
-17,000
-3% -$206K
TBLA icon
28
Taboola.com
TBLA
$1.37B
$7.47M 1.2%
+1,724,948
New +$6.52M
AMD icon
29
Advanced Micro Devices
AMD
$776B
$7.43M 1.2%
50,387
+2,067
+4% +$244K
PRAX icon
30
Praxis Precision Medicines
PRAX
$8.58B
$7.33M 1.18%
328,986
+5,632
+2% +$101K
ABBV icon
31
AbbVie
ABBV
$443B
$7.13M 1.15%
46,000
– –
WIX icon
32
WIX.com
WIX
$2.3B
$7.07M 1.14%
+57,477
New +$5.55M
ALNY icon
33
Alnylam Pharmaceuticals
ALNY
$27.5B
$6.93M 1.12%
36,230
+129
+0.4% +$22K
PHVS icon
34
Pharvaris
PHVS
$2.28B
$6.87M 1.11%
+245,000
New +$4.96M
INZY
35
DELISTED
Inozyme Pharma
INZY
$6.66M 1.07%
1,562,907
+328,000
+27% +$1.17M
IMTX icon
36
Immatics
IMTX
$1.18B
$6.54M 1.05%
621,111
+3,938
+0.6% +$36.3K
MDGL icon
37
Madrigal Pharmaceuticals
MDGL
$10.8B
$6.42M 1.03%
27,767
-23,100
-45% -$4.04M
MLYS icon
38
Mineralys Therapeutics
MLYS
$2.25B
$6.39M 1.03%
743,591
+288,191
+63% +$2.26M
MRUS
39
DELISTED
Merus
MRUS
$6.33M 1.02%
230,333
-23,000
-9% -$537K
SWTX
40
DELISTED
SpringWorks Therapeutics
SWTX
$6.21M 1%
170,270
-149,641
-47% -$3.91M
NVS icon
41
Novartis
NVS
$297B
$6.06M 0.98%
60,000
– –
S icon
42
SentinelOne
S
$6.53B
$5.86M 0.94%
+213,418
New +$4.13M
RCKT icon
43
Rocket Pharmaceuticals
RCKT
$340M
$5.72M 0.92%
190,783
-18,257
-9% -$403K
JSPR icon
44
Jasper Therapeutics
JSPR
$21M
$5.63M 0.91%
71,306
-497,407
-87% -$3.34M
INCY icon
45
Incyte
INCY
$24.2B
$5.62M 0.91%
+89,556
New +$5.07M
GRCL
46
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$5.05M 0.81%
502,936
-1,028,561
-67% -$4.67M
SHLT
47
DELISTED
SHL Telemedicine Ltd American Depositary Shares
SHLT
$5.04M 0.81%
632,456
+200
+0% +$1.89K
PANW icon
48
Palo Alto Networks
PANW
$270B
$4.89M 0.79%
33,170
-24,348
-42% -$3.26M
ENPH icon
49
Enphase Energy
ENPH
$4.96B
$4.6M 0.74%
+34,800
New +$3.69M
CLDX icon
50
CALL
Celldex Therapeutics
CLDX
$2.99B
$4.59M 0.74%
115,700
+15,700
+16% +$462K
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2023 Portfolio in Review

As of Q4 2023, Sphera Funds Management held 112 positions worth $621M, up 13% from $549M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Sphera Funds Management withdrew a net $24.9M in Q4 2023, closing 13 positions and reducing 32 holdings. Its most notable exit was POINT Biopharma Global Inc. Common Stock, an estimated $6.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 61% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Sphera Funds Management opened a new position in Nova worth $18.1M.

  • Sphera Funds Management's largest Q4 2023 buy was Nova: 132,000 shares worth $18.1M.
  • Sphera Funds Management added most to Teva Pharmaceuticals in Q4 2023, an estimated $17.5M increase.
  • Sphera Funds Management's biggest Q4 2023 reduction was AstraZeneca, cutting an estimated $6.82M.
  • Sphera Funds Management fully exited POINT Biopharma Global Inc. Common Stock in Q4 2023, selling an estimated $6.35M.
  • Sphera Funds Management's ten largest holdings make up 33% of its $621M portfolio in Q4 2023.
  • Sphera Funds Management opened 30 new positions and closed 13 in Q4 2023.
  • Sphera Funds Management's portfolio value rose 13% quarter-over-quarter to $621M.

Based on Sphera Funds Management's 13F filing for Q4 2023, filed 14 Feb 2024.